Goserelin CAS:65807-02-5

Goserelin is an analog of luteinizing hormone-releasing hormone (LHRH) useful in the treatment of malignancies responsive to hormonal manipulation. Administered parenterally in a biodegradable depot, goserelin is reportedly as effective as orchidectomy and oophorectomy in patients with advanced prostate carcinoma and pre-menopausal breast cancer.

1. Gonadorelin is another name for gonadotropin-releasing hormone (GnRH). It is a synthetic decapeptide prepared using solid phase peptide synthesis. GnRH is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary.

2. GnRH is available as gonadorelin hydrochloride )and gonadorelin diacetate tetrahydrate for injectable use. Studies have described it being used via an infusion pump system to induce ovulation in patients with hypothalamic hypogonadism. It is also used in veterinary medicine as a treatment for cattle with cystic ovarian disease.

3. Gonadorelin is responsible for the release of follicle stimulating hormone and leutinizing hormone from the anterior pitutitary. In the pituitary GnRH stimulates synthesis and release of FSH and LH, a process that is controlled by the frequency and amplitude of GnRH pulses, as well as the feedback of androgens and estrogens.

男性

Palliative treatment of advanced carcinoma of the prostate; in combination with flutamide for management of locally confined stage T2b to T4 (stage B2 to C) carcinoma of the prostate.

Women (3.6 mg only)

Palliative treatment of advanced breast cancer in pre- and perimenopausal women; treatment of endometriosis; as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding.